MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria featured in The New York Times, The Soul of a New Vaccine
The sign on the wall reads “Emergency Response Procedures for a Mosquito Release.” Among them are “Do Not Leave the Room or Open Any Doors!!!” and “Do Not Panic!” Everything in the room is white, including the lab coats and surgical masks — for sterility, yes, but also the better to see a mosquito. Hanging next to the sign, in vivid Coast Guard orange, is the last line of defense, a brace of fly swatters. This room, the mosquito dissection lab, in an unassuming biotech park in the Washington suburbs, is at the heart of one of the most controversial ideas in vaccine science. Sanaria Inc. (meaning “healthy air,” a play on the Italian “mal’aria” or “bad air”) is making a vaccine the old-fashioned way, more or less as Louis Pasteur did. Read the full article and see the photos in The New York Times.
Sanaria CEO, Dr. Stephen L. Hoffman, interviewed on Al Jazeera English’s: The Pulse
Despite millions of dollars being spent on research there is no vaccine available against one of the world's biggest killer diseases -- Malaria. The Pulse looks at the parasite that has proved too complex for scientists and visits a clinical trial in Tanzania, which is showing unusual promise.
Adel A. F. Mahmoud, M.D., Ph.D joins Sanaria Board of Directors
Sanaria is pleased to announce that Adel A. F. Mahmoud, M.D., Ph.D, of the Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University and former President of Merck Vaccines, was elected to Sanaria's Board of Directors.
Whole parasite malaria vaccine to be manufactured for clinical trials
Sanaria Inc. and the PATH Malaria Vaccine Initiative has officially opened a one-of-a- kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.
Researchers aim to use mosquitoes to bite back at malaria
A US scientist is leading an international team of researchers using an army of blood- sucking mosquitoes to produce a potentially potent vaccine against malaria.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.